Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

Journal of Infectious Diseases

Volumn 189, Issue 10, 2004, Pages 1802-1810

  Colonno, Richard ^a   Rose, Ronald ^a   McLaren, Colin ^a   Thiry, Alexandra ^a   Parkin, Neil ^b   Friborg, Jacques ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ISOLEUCINE; LEUCINE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS ACTIVATION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

BASE SEQUENCE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; POINT MUTATION; PYRIDINES; REASSORTANT VIRUSES; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

EID: 2442657656     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/386291     Document Type: Article

References (32)

1. Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000; 14:1203-10.
2. Voelker R. HIV drug resistance. JAMA 2000; 284:169.
3. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275:318-22.
4. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000; 14:1489-95.
5. Schmidt B, Walter H, Moschik B, et al. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 2000; 14:1731-8.
6. Rabasseda X, Silvestre JS, Castañer J. BMS-232632. Drugs Future 1999; 24:375-80.
7. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44:2093-9.
8. + patients (AI424-008) [abstract 1-667]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:323.
9. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: combination of antiviral efficacy and safety through week 24 (AI424-034) [abstract M-1076]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:267.
10. Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-26.
11. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47:1324-33.
12. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, Group A-CT. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
13. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-14.
14. Murphy R, Pokrovskiy V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir (ATV) with stavudine (d4T) and lamivudine (3TC) in patients previously treated with nelfinavir (NFV) or ATV: 108-week results of BMS study 008/044 [abstract 555]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:254.
15. Johnson VA, Byington RE. Infectivity assay (virus yield assay). In: Walker BD, ed. Techniques in HIV research. New York: Stockton Press, 1990:71-6.
16. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann N, Petropoulos C. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002; 31:128-36.
17. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-8.
18. Potts B. Mini reverse transcriptase (RT) assay. In: Walker B, ed. Techniques in HIV research. New York: Stockton Press, 1990:103-6.
19. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:1209-13.
20. Cote HCF, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 2001; 75:589-94.
21. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70:3763-9.
22. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7.
23. Zhang Y, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71:6662-70.
24. Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2003; 47:759-69.
25. Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-406.
26. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 2000; 283:2417-26.
27. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998; 42:2637-44.
28. Quinones-Mateu M, Arts E. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat 2002; 5:224-33.
29. Shenderovich MD, Kagan RM, Heseltine PNR, Ramnarayan K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci 2003; 12:1706-18.
30. Maguire M, Shortino D, Klein A, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46:731-8.
31. Tisdale M, Myers R, Maschera B, Parry N, Oliver N, Blair E. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39:1704-10.
32. Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J Virol 2002; 76:8659-66.